Hiroshi Shirasawa

Hiroshi Shirasawa

Auto-generated profile, based on publicly available information

Hiroshi Shirasawa

Department of Molecular Virology, Graduate School of Medicine, Chiba University, Chiba, Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in Antiviral Research
Verified
Journal Article
Closed access
MKMasakazu Kono
Masakazu Kono
KTKoichiro Tatsumi
Koichiro Tatsumi
AIAlberto M. Imai
Alberto M. Imai
KSKengo Saito
Kengo Saito
TKTakayuki Kuriyama
Takayuki Kuriyama
HSHiroshi Shirasawa
Hiroshi Shirasawa

1 October 2007 in Virus Genes
Verified
Journal Article
Closed access
PDF file
YTYoshimi Tomita
Yoshimi Tomita
ILIvan Literak
Ivan Literak
TOTomoko Ogawa
Tomoko Ogawa
ZJZhongri Jin
Zhongri Jin
HSHiroshi Shirasawa
Hiroshi Shirasawa

Verified
Journal Article
Open access
PDF file
Shingo NakamotoShingo Nakamoto
Shingo Nakamoto
Tatsuo KandaTatsuo Kanda
Tatsuo Kanda
CNChiaki Nakaseko
Chiaki Nakaseko
ESEmiko Sakaida
Emiko Sakaida
COChikako Ohwada
Chikako Ohwada
OYOSAMU YOKOSUKA
OSAMU YOKOSUKA
We retrospectively reviewed 413 recipients with hematologic malignancies who underwent hematopoietic stem cell transplantation (HSCT) between June 1986 and March 2013. Recipients with antibody to hepatitis B core antigen (anti-HBc) and/or to hepatitis B surface antigen (anti-HBs) were regarded as experiencing previous hepatitis B virus (HBV) infection. Clinical data of these recipients were reviewed from medical records. We defined ≥1 log IU/mL increase in serum HBV DNA from nadir as HBV reactivation in hepatitis B surface antigen (HBsAg)-positive recipients, and also defined ≥1 log IU/mL increase or re-appearance of HBV DNA and/or HBsAg as HBV reactivation in HBsAg-negative recipients. In 5 HBsAg-positive recipients, 2 recipients initially not administered with nucleos(t)ide analogues (NUCs) experienced HBV reactivation, but finally all 5 were successfully controlled with NUCs. HBV reactivation was observed in 11 (2.7%) of 408 HBsAg-negative recipients; 8 of these were treated with NUCs, and fortunately none developed acute liver failure. In 5 (6.0%) of 83 anti-HBc and/or anti-HBs-positive recipients, HBV reactivation occurred. None of 157 (0%) recipients without HBsAg, anti-HBs or anti-HBc experienced HBV reactivation. In HSCT recipients, HBV reactivation is a common event in HBsAg-positive recipients, or in HBsAg-negative recipients with anti-HBc and/or anti-HBs. Further attention should be paid to HSCT recipients with previous exposure to HBV.

23 August 2015 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
ATAyako Takenouchi
Ayako Takenouchi
KSKengo Saito
Kengo Saito
ESEriko Saito
Eriko Saito
TSTakeshi Saito
Takeshi Saito
THTomoro Hishiki
Tomoro Hishiki
HSHiroshi Shirasawa
Hiroshi Shirasawa

14 April 2022 in Virus Research
Verified
Journal Article
Closed access
RMRyosuke Muroyama
Ryosuke Muroyama
RNRyo Nakagawa
Ryo Nakagawa
YMYasuo Matsubara
Yasuo Matsubara
YHYoshihiro Hirata
Yoshihiro Hirata
MOMasao Omata
Masao Omata
NKNaoya Kato
Naoya Kato

1 January 2005 in Acta Oto-Laryngologica
Verified
Journal Article
Closed access
KKKeiichiro Kumahara
Keiichiro Kumahara
HNHiroshi Nagata
Hiroshi Nagata
KWKen Watanabe
Ken Watanabe
NSNorio Shimizu
Norio Shimizu
YAYukiko Arimoto
Yukiko Arimoto
HSHiroshi Shirasawa
Hiroshi Shirasawa
Conclusion. The results of this study demonstrate that suppression of inflammation by dexamethasone attenuates the host immune response against adenoviral-mediated gene transfection and thereby prolongs transgene expression in murine nasal mucosa. Objectives. Gene transfer using a recombinant adenovirus is a good tool for research and clinical applications, but the immune response to adenoviral vectors can induce inflammation and loss of transgene expression in transfected tissues. In this study we investigated the effects of dexamethasone-induced immunosuppression on adenovirus gene transfer in the nasal mucosa of the mouse. Material and methods. We administered the recombinant adenovirus Ax1CAlacZ, which encodes Escherichia coli β-galactosidase (lacZ gene), to the nasal mucosa of mice treated with or without i.p. dexamethasone and evaluated the expression of the lacZ gene on Days 2, 4, 7, 14 and 28. The nasal mucosa was dissected out, and the mRNA level was measured using a LightCycler. The expression of the exogenous β-galactosidase was detected by means of histochemistry. Results. Dexamethasone treatment significantly increased the mRNA level compared with that in the controls at Days 4, 7 and 14. Histochemistry showed that the expression of β-galactosidase protein persisted in the dexamethasone-treated mice at Days 7 and 14 but had diminished almost to nothing in the control group.